{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:16:35Z","timestamp":1790388995531,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>\n                    Bone and joint infections present a significant therapeutic challenge in children, particularly in complex or chronic cases.\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    is the most common causative pathogen, with methicillin resistance rates varying by geographic location and hospital setting, underscoring the need for antibiotics effective against both methicillin-sensitive\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    and methicillin-resistant\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    . Daptomycin, a cyclic lipopeptide antibiotic effective against gram-positive pathogens, is increasingly used off-label in pediatric osteomyelitis. This prospective study evaluates its real-world application, focusing on clinical outcomes, dosing strategies, safety, and therapeutic potential. Over a 3-year period, 20 children (median age: 13.5 years) with bone and joint infections were treated with daptomycin. The patient cohort was highly complex, with 70% having severe orthopedic or medical comorbidities. Methicillin-sensitive\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    was isolated in 60% of cases, while\n                    <jats:italic toggle=\"yes\">MRSA<\/jats:italic>\n                    was identified in 35%. Daptomycin was administered following bacteremia dosing guidelines, with some patients receiving higher doses (mean: 10 mg\/kg). The median duration of daptomycin therapy was 24.5 days. Treatment was successful in 90% of cases, often transitioning to oral antibiotic therapy. C-reactive protein levels showed a median reduction of 90%. A composite score evaluating clinical response\u2014including C-reactive protein levels, type of continuation therapy, and the need for surgery\u2014indicated substantial improvement in the majority of patients, with a median score of 4. No severe adverse events were recorded, though transient neutropenia and elevated creatine kinase levels were observed in 2 cases. This study underscores daptomycin\u2019s safety and efficacy in treating complex pediatric osteoarticular infections and suggests its potential as a first-line therapy, particularly for MRSA cases. The comprehensive data reflect the current microbiological landscape of pediatric bone and joint infections, supporting the reconsideration of daptomycin\u2019s role in initial treatment protocols. Further research and controlled trials are warranted to confirm these findings and optimize treatment strategies.\n                  <\/jats:p>","DOI":"10.1097\/inf.0000000000004804","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T17:05:16Z","timestamp":1742403916000},"page":"e291-e295","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Daptomycin for Pediatric Complex Bone and Joint Infections: Real-world Efficacy and Safety Data from a Three-year Study"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8495-1844","authenticated-orcid":false,"given":"Marco","family":"Denina","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Infectious Diseases Unit, University of Turin, Regina Margherita Children\u2019s Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Abrate","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Public Health, University of Turin, Regina Margherita Children\u2019s Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Silvestro","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Infectious Diseases Unit, University of Turin, Regina Margherita Children\u2019s Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Funiciello","sequence":"additional","affiliation":[{"name":"Department of Pediatric Onco-Hematology, University of Turin, Regina Margherita Children\u2019s Hospital, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pruccoli","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Infectious Diseases Unit, University of Turin, Regina Margherita Children\u2019s Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Sandei","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Public Health, University of Turin, Regina Margherita Children\u2019s Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Mazzetti","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Public Health, University of Turin, Regina Margherita Children\u2019s Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Garazzino","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Infectious Diseases Unit, University of Turin, Regina Margherita Children\u2019s Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"R1-20250723","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/INF.0000000000001635","article-title":"Bone and joint infections.","volume":"36","author":"Saavedra-Lozano","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R2-20250723","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/INF.0000000000003067","article-title":"The contemporary epidemiology, microbiology and management of chronic osteomyelitis in US children.","volume":"40","author":"McNeil","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"R4-20250723","first-page":"47","article-title":"Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections.","volume":"9","author":"Gonzalez-Ruiz","year":"2016","journal-title":"Infect Drug Resist"},{"key":"R6-20250723","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMra1213956","article-title":"Acute osteomyelitis in children.","volume":"370","author":"Peltola","year":"2014","journal-title":"N Engl J Med"},{"key":"R7-20250723","doi-asserted-by":"crossref","first-page":"104431","DOI":"10.1016\/j.micpath.2020.104431","article-title":"A comprehensive review of bacterial osteomyelitis with emphasis on Staphylococcus aureus.","volume":"148","author":"Nasser","year":"2020","journal-title":"Microb Pathog"},{"key":"R8-20250723","article-title":"Antimicrobial resistance in the EU\/EEA (EARS-Net) - Annual epidemiological report for 2022.","year":"2023"},{"key":"R9-20250723","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research.","volume":"17","author":"Turner","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"R10-20250723","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R11-20250723","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5694\/j.1326-5377.2006.tb00189.x","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus in bone and joint infections: development of rifampicin resistance.","volume":"184","author":"Donaldson","year":"2006","journal-title":"Med J Aust"},{"key":"R12-20250723","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jpids\/piy062","article-title":"Increasing clindamycin and trimethoprim-sulfamethoxazole resistance in pediatric Staphylococcus aureus infections.","volume":"8","author":"Khamash","year":"2019","journal-title":"J. Pediatric Infect. Dis. Soc"},{"key":"R13-20250723","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1086\/381762","article-title":"Linezolid-induced neuropathy.","volume":"38","author":"Legout","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R14-20250723","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bjid.2019.05.006","article-title":"Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review.","volume":"23","author":"Telles","year":"2019","journal-title":"Braz J Infect Dis"},{"key":"R15-20250723","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/INF.0000000000001076","article-title":"Clinical experience with daptomycin for the treatment of Gram-positive infections in children and adolescents.","volume":"35","author":"Syriopoulou","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20250723","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/INF.0000000000002790","article-title":"Daptomycin for pediatric Gram-positive acute hematogenous osteomyelitis.","volume":"39","author":"Bradley","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"R17-20250723","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/jpids\/piab027","article-title":"Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics.","volume":"10","author":"Woods","year":"2021","journal-title":"J. Pediatric Infect. Dis. Soc"},{"key":"R18-20250723","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/01.bpo.0000242431.91489.b4","article-title":"Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureus.","volume":"26","author":"Arnold","year":"2006","journal-title":"J Pediatr Orthop"},{"key":"R19-20250723","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1093\/jac\/dkx314","article-title":"Intraosteoblastic activity of daptomycin in combination with oxacillin and ceftaroline against MSSA and MRSA.","volume":"72","author":"Dupieux","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R20-20250723","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1128\/AAC.48.8.2871-2875.2004","article-title":"Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus.","volume":"48","author":"Rand","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20250723","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/INF.0000000000001926","article-title":"Randomized multicenter study comparing safety and efficacy of daptomycin versus standard-of-care in pediatric patients with staphylococcal bacteremia.","volume":"37","author":"Arrieta","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20250723","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1128\/AAC.00208-09","article-title":"Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.","volume":"53","author":"Murillo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20250723","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1128\/AAC.02344-14","article-title":"Penetration of daptomycin into bone and synovial fluid in joint replacement.","volume":"58","author":"Montange","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-20250723","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12879-016-1420-7","article-title":"Daptomycin > 6 mg\/kg\/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center.","volume":"16","author":"Roux","year":"2016","journal-title":"BMC Infect Dis"},{"key":"R25-20250723","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.diagmicrobio.2014.05.022","article-title":"High doses of daptomycin (10 mg\/kg\/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study.","volume":"80","author":"Lora-Tamayo","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R26-20250723","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1345\/aph.1M085","article-title":"Safety and clinical outcomes when utilizing high-dose (> or =8 mg\/kg) daptomycin therapy.","volume":"43","author":"Moise","year":"2009","journal-title":"Ann Pharmacother"},{"key":"R27-20250723","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/cid\/ciad386","article-title":"Daptomycin exposure as a risk factor for daptomycin-induced eosinophilic pneumonia and muscular toxicity.","volume":"77","author":"Garreau","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R28-20250723","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection.","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T20:00:31Z","timestamp":1753300831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004804","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]}}}